Nanobiotix (NASDAQ:NBTX) Sees Unusually-High Trading Volume – What’s Next?

Shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) saw unusually-strong trading volume on Thursday . Approximately 119,459 shares were traded during mid-day trading, an increase of 45% from the previous session’s volume of 82,617 shares.The stock last traded at $45.05 and had previously closed at $44.50.

Wall Street Analyst Weigh In

NBTX has been the topic of a number of recent analyst reports. Leerink Partners lifted their price target on Nanobiotix from $37.00 to $46.00 and gave the company an “outperform” rating in a report on Thursday, June 4th. HC Wainwright reissued a “buy” rating on shares of Nanobiotix in a report on Monday, May 18th. UBS Group increased their price objective on Nanobiotix from $3.50 to $30.00 and gave the stock a “neutral” rating in a report on Friday, May 1st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a research report on Friday, July 17th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $37.33.

Nanobiotix Price Performance

The firm’s fifty day moving average is $39.24 and its two-hundred day moving average is $36.10.

Institutional Trading of Nanobiotix

A number of hedge funds and other institutional investors have recently made changes to their positions in NBTX. Royal Bank of Canada boosted its holdings in shares of Nanobiotix by 2,000.0% in the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after acquiring an additional 2,500 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Nanobiotix during the fourth quarter valued at approximately $220,000. Finally, Millennium Management LLC bought a new stake in Nanobiotix during the fourth quarter worth approximately $390,000. 38.81% of the stock is currently owned by institutional investors.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.